Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus

OBJECTIVE: To examine whether lowering plasma glucose concentration with the sodium-glucose transporter-2 inhibitor empagliflozin improves β-cell function in patients with type 2 diabetes mellitus (T2DM). METHODS: Patients with T2DM (N = 15) received empagliflozin (25 mg/d) for 2 weeks. β-Cell funct...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Endocrinol Metab
Päätekijät: Al Jobori, Hussein, Daniele, Giuseppe, Adams, John, Cersosimo, Eugenio, Solis-Herrera, Carolina, Triplitt, Curtis, DeFronzo, Ralph A, Abdul-Ghani, Muhammad
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Endocrine Society 2018
Aiheet:
Clinical Research Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7328850/
https://ncbi.nlm.nih.gov/pubmed/29342295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2017-01838
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia